264 related articles for article (PubMed ID: 31467225)
1. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
3. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
[TBL] [Abstract][Full Text] [Related]
4. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M
Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862
[TBL] [Abstract][Full Text] [Related]
5. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
[TBL] [Abstract][Full Text] [Related]
8. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
[TBL] [Abstract][Full Text] [Related]
9.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
10. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
[TBL] [Abstract][Full Text] [Related]
11. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
[TBL] [Abstract][Full Text] [Related]
12. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
[TBL] [Abstract][Full Text] [Related]
14. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
[TBL] [Abstract][Full Text] [Related]
15. CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings.
Martini I; Polici M; Zerunian M; Panzuto F; Rinzivillo M; Landolfi F; Magi L; Caruso D; Eid M; Annibale B; Laghi A; Iannicelli E
Eur J Radiol; 2020 Mar; 124():108812. PubMed ID: 31951893
[TBL] [Abstract][Full Text] [Related]
16. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
[TBL] [Abstract][Full Text] [Related]
17. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
18. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Kim D; Viswanathan K; Goyal A; Rao R
Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
[TBL] [Abstract][Full Text] [Related]
19. The Role of Surgery for Pancreatic Neuroendocrine Tumors.
Ziogas IA; Schmitz R; Moris D; Vatsaas CJ
Anticancer Res; 2022 Feb; 42(2):629-639. PubMed ID: 35093860
[TBL] [Abstract][Full Text] [Related]
20. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness.
Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ
J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
